Cerevel Therapeutics Holdings Inc (CERE)
41.54
-0.06
(-0.13%)
USD |
NASDAQ |
Jun 14, 16:00
41.54
0.00 (0.00%)
Pre-Market: 20:00
Cerevel Therapeutics Holdings Research and Development Expense (TTM): 362.88M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 362.88M |
| December 31, 2023 | 334.64M |
| September 30, 2023 | 318.83M |
| June 30, 2023 | 304.96M |
| March 31, 2023 | 303.42M |
| December 31, 2022 | 280.26M |
| September 30, 2022 | 246.79M |
| Date | Value |
|---|---|
| June 30, 2022 | 215.56M |
| March 31, 2022 | 180.32M |
| December 31, 2021 | 161.86M |
| September 30, 2021 | 144.15M |
| June 30, 2021 | 128.02M |
| March 31, 2021 | 112.90M |
| December 31, 2020 | 103.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
103.30M
Minimum
Dec 2020
362.88M
Maximum
Mar 2024
228.42M
Average
231.18M
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie Inc | 7.322B |
| Bristol-Myers Squibb Co | 9.673B |
| Amgen Inc | 5.069B |
| Biogen Inc | 2.344B |
| Reviva Pharmaceuticals Holdings Inc | 31.97M |